In Brief: Cardiac Pacemakers, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Cardiac Pacemakers, Inc.: Guidant unit plans to begin shipments of its Vigor DR and SR adaptive rate pulse generators the week of June 26 following receipt of FDA premarket approval. The dual-chamber DR will list for $7,295 while the single-chamber SR will sell for $6,295, the firm says. The pacer systems "use an advanced accelerometer technology to monitor the patient's physical activity and provide rate modulation to meet the patient's needs." FDA's Circulatory System Devices Panel unanimously recommended approval of the products May 9 ("The Gray Sheet" May 15, p. 10)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.